Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Fineline Cube Sep 11, 2026
Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026
Company Drug

Laekna’s LAE120 Receives FDA Approval for Solid Tumor Clinical Trials

Fineline Cube Mar 3, 2025

Sino-US biotech company Laekna, Inc. (HKG: 2105) announced that it has received clinical trial approval...

Company Drug

SynerK’s SNK-2726 Gets FDA Green Light for Phase I Hypertension Study

Fineline Cube Mar 3, 2025

SynerK, an RNA-targeted therapy developer with operations in Boston, US, and Beijing and Suzhou, China,...

Company Deals

Omron Healthcare and China Jo-Jo Drugstores Launch Atrial Fibrillation Screening Zone

Fineline Cube Mar 3, 2025

A joint effort between Japan-based Omron Healthcare and China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD), a...

Company Deals

WORK Medical and Chartwell Med Partner on Investment Tools for Healthcare Projects

Fineline Cube Mar 3, 2025

WORK Medical Technology Group Ltd (NASDAQ: WOK), a medical consumables company based in Hangzhou, has...

Company Drug

Innovent Biologics Doses First Patient in IBI363 Melanoma Study vs Keytruda

Fineline Cube Mar 3, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced the first patient dosing in the pivotal regulatory...

Deals Drug

Eyebright Medtech Plans Private Placement to Expand Contact Lens Production

Fineline Cube Mar 3, 2025

China-based Eyebright Medical Technology (Beijing) Co., Ltd. (SHA: 688050), an ophthalmic medical device manufacturer, announced...

Company Drug

Sinocelltech’s Finotonlimab Gets NMPA Approval for Liver Cancer Treatment

Fineline Cube Mar 3, 2025

China-based Sinocelltech Group Ltd (SHA: 688520) announced that it has received another indication approval from...

Company Deals

Danatlas Raises RMB 150M to Advance Synthetic Lethality Drug Pipeline

Fineline Cube Mar 3, 2025

Beijing-headquartered Danatlas, a first-in-class drug developer in the synthetic lethality field, has reportedly raised RMB...

Company Deals

Magnet Biomedicine and Eli Lilly Partner on Molecular Glue Therapeutics

Fineline Cube Mar 3, 2025

US-based molecular glue specialist Magnet Biomedicine has entered into a collaboration and license agreement with...

Company Drug

AstraZeneca and Amgen’s Tezspire Shows Positive Results in Phase III Study

Fineline Cube Mar 3, 2025

AstraZeneca (NASDAQ: AZN) and Amgen (NASDAQ: AMGN) have jointly announced positive results from the Phase...

Company Deals Digital

Baidu Health Partners with Jolly Pharma to Boost Digital Drug Marketing

Fineline Cube Mar 3, 2025

Baidu Health, an internet giant, has entered into a partnership with Zhejiang Jolly Pharmaceutical Co.,...

Company Deals

Duality Biotherapeutics Updates IPO Filing with HKSE under Chapter 18A Rules

Fineline Cube Mar 3, 2025

China-based Duality Biotherapeutics, Inc. updated its initial public offering (IPO) filing to the Hong Kong...

Company Drug

CARsgen’s CT041 Awarded Breakthrough Therapy Designation for Gastric Cancer

Fineline Cube Mar 3, 2025

CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced that its chimeric antigen receptor (CAR) T-cell therapy,...

Company Deals

Huge Dental Files for Hong Kong IPO with Diverse Dental Product Portfolio

Fineline Cube Mar 3, 2025

Shandong-based dental materials company Huge Dental Limited has made an initial public offering (IPO) filing...

Drug

CSPC Pharmaceutical’s Sirolimus Receives BTD for Malignant PEComa Treatment

Fineline Cube Mar 3, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received Breakthrough Therapy Designation...

Company Deals

Pulnovo Medical Raises USD 100M in Series C Financing for Global Expansion

Fineline Cube Mar 3, 2025

Wuxi-based Pulnovo Medical Limited, a developer of medical devices for pulmonary hypertension and heart failure,...

Company Deals

Grand Pharma Sells Telix Shares for AUD 143M to Fund Clinical Programs

Fineline Cube Mar 3, 2025

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced the sale of 4,947,181 shares in...

Company

AI in Healthcare: Accelerating Applications in Diagnostics and Multi-omics Analysis

Fineline Cube Mar 2, 2025

The breakthrough technology of DeepSeek has significantly accelerated the application of AI in the medical...

Company

Biointron Biologics Files for Public Offering, Aims for BSE Listing

Fineline Cube Mar 2, 2025

On February 11, Biointron Biologics released its tutoring filing report for the public offering of...

Company

Biocytogen Completes DeepSeek Localization, Integrates with “Thousand Mice, Ten Thousand Antibodies” Plan

Fineline Cube Mar 1, 2025

On February 28, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that it has completed...

Posts pagination

1 … 257 258 259 … 719

Recent updates

  • Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
  • BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis
  • Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China
  • China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories
  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.